All Boards >> Irritable Bowel Syndrome Research Library

View all threads Posts     Flat     Threaded

Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
      11/26/06 02:39 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7795
Loc: Seattle, WA

Efficacy of Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS


David A. Johnson, MD, FACG, FACP

The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y

Ann Intern Med. 2006;145:557-563

Summary
Irritable bowel syndrome (IBS) is a prevalent condition that has been labeled as a "functional bowel disorder." By this delineation, its cause has been thought to be indefinable. The primary symptoms of this disorder include constipation, diarrhea, abdominal bloating, and cramping. Recent attention has focused on a potential infectious component of IBS.

In this study, Pimental and colleagues investigated the use of rifaximin in patients diagnosed with IBS as defined by the Rome I criteria. Rifaximin is a nonabsorbable, gut-selective antibiotic derived from the rifamycin family that may reduce bacterial overgrowth due to its broad-spectrum activity in vitro against gram-positive, gram-negative, aerobic, anaerobic, and microaerophilic bacteria.

This was a prospective, double-blind randomized controlled trial that involved 43 patients who received 400 mg of rifaximin 3-times daily and 44 who received placebo for 10 days. Patient symptom and stool diaries were completed prior to entry, during the study, and the week following treatment.

Global improvement was found to vary widely across weeks for most patients, and the data were reported as an averaging of the symptoms over all 10 weeks of the study. This percentage was significant as a function of group (P = .020), but not as a function of week (P = .78) or group-by-week (P = .96). The patients in the rifaximin group had a 36.4% improvement in global symptoms compared with 21.0% for the placebo group.

The rifaximin group also reported significantly less bloating on a visual analog scale compared with the placebo group (P = .010), a difference that persisted after controlling for differences between groups in baseline pain scores (P = .001). Besides bloating, none of the secondary endpoints improved with treatment compared with placebo on the visual analog scale: abdominal pain (P = .32), diarrhea (P = .67), and constipation (P = .069).

Viewpoint
Rifaximin is currently US Food and Drug Administration-approved for the treatment of traveler's diarrhea, although these study findings suggest a more expanded potential role for this antibiotic. However, before recommending widespread globalized use of this medication for all patients with IBS, healthcare providers should be aware of several limitations of this study. First, although this was a "multicenter study," there was a considerable imbalance between enrollment from the 2 study sites (83 participants vs 3 participants). Second, because the global measure includes pain, it is important to note that there was an imbalance in baseline pain scores between the 2 patient groups at entry. The imbalance (higher baseline pain scores in the rifaximin group) potentially favors the reduction in the global scores. Additionally, this primary outcome measure is unique in the spectrum of the recent treatment intervention evaluations for IBS trials, and therefore makes comparisons with other trials somewhat difficult. Third, the study authors relied solely on the use of the lactose breath test to define small bowel bacterial overgrowth. Future tests in this area should evaluate the use of other breath tests to define bacterial overgrowth in the small intestine. Fourth, the data suggest that rifaximin may be of more help in the subset of patients with bloating. In IBS, abdominal bloating is reported in more than 50% of patients, and a recent study suggests that changes in abdominal girth can reach 12 cm in more than 50% of patients.[1]

Clearly, this study highlights a new concept in the potential pathogenesis of IBS. An infectious cause may offer a tremendous opportunity to manage an otherwise somewhat frustrating disease -- both for patients and their treating physicians.

Abstract

References
Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology. 2006;131:1003-1010.


David A. Johnson, MD, FACG, FACP, Professor of Medicine, Chief of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia


David A. Johnson, MD, FACG, FACP, has disclosed that he has received grants for clinical research from AstraZeneca, TAP, Wyeth, Novartis, and Abbott, and grants for educational activities from AstraZeneca and Novartis. Dr. Johnson has also disclosed that he has served as an advisor or consultant to AstraZeneca, TAP, and Novartis.


Medscape Gastroenterology. 2006;8(2) 2006 Medscape

http://www.medscape.com/viewarticle/547055?src=mp

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Entire thread
* Pharmaceutical
HeatherAdministrator
07/14/03 01:50 PM
* Medical Marijuana Significant for Migraines, Fibromyalgia, and IBS
HeatherAdministrator
02/16/21 01:21 PM
* Heartburn drugs that are proton pump inhibitors could trigger IBS and SIBO
HeatherAdministrator
12/07/20 01:28 PM
* For IBS Patients, Cannabis Linked to Fewer Rehospitalizations
HeatherAdministrator
05/05/20 02:14 PM
* Cannabis could help a person defecate
HeatherAdministrator
04/14/20 12:17 PM
* FDA OKs Reintroduction of Tegaserod (Zelnorm) for IBS-C in Women Under 65
HeatherAdministrator
04/04/19 02:45 PM
* Long-term cannabis use increases risk for IBS
HeatherAdministrator
10/19/17 04:04 PM
* FDA approves new drug for chronic constipation
HeatherAdministrator
01/26/17 03:05 PM
* Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D
HeatherAdministrator
01/27/16 02:48 PM
* Low-dose naltreoxone for the treatment of irritable bowel syndrome
HeatherAdministrator
01/26/16 01:20 PM
* Amitiza benefited patients with chronic idiopathic constipation
HeatherAdministrator
02/10/15 04:15 PM
* Medical Marijuana for Digestive Disorders: High Time to Prescribe?
HeatherAdministrator
09/17/14 02:08 PM
* Antibiotics Early in Life May Boost Obesity Risk
HeatherAdministrator
08/18/14 03:13 PM
* Antidepressants, psychological therapies effectively treated IBS
HeatherAdministrator
07/15/14 02:49 PM
* Proton pump inhibitor (acid reflux drugs) may cause heart disease
HeatherAdministrator
09/23/13 03:22 PM
* Older drugs are better than new ones
HeatherAdministrator
06/13/13 02:00 PM
* On Anti-Depressants? Some Raise Risk of C. Diff Infection
HeatherAdministrator
05/13/13 05:51 PM
* Heartburn drugs, NSAID painkillers use linked to IBS symptoms
HeatherAdministrator
03/18/13 01:24 PM
* FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation
HeatherAdministrator
08/31/12 11:25 AM
* 3-month FDA delay for potential IBS drug linaclotide
HeatherAdministrator
04/23/12 01:45 PM
* Latest FDA watch list includes GI drugs
HeatherAdministrator
04/23/12 01:42 PM
* Antibiotics that reduce gut bacteria linked to obesity
HeatherAdministrator
05/06/11 12:25 PM
* Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
HeatherAdministrator
02/10/11 10:23 AM
* Antacids increase risk of pneumonia
HeatherAdministrator
01/14/11 04:35 PM
* Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome
HeatherAdministrator
01/07/11 03:01 PM
* Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation
HeatherAdministrator
01/07/11 02:59 PM
* Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk
HeatherAdministrator
11/10/10 11:29 AM
* Phase 3 clinical trials of linaclotide for IBS constipation
HeatherAdministrator
10/13/10 02:44 PM
* An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent
HeatherAdministrator
07/16/10 03:17 PM
* Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C
HeatherAdministrator
04/07/10 01:32 PM
* Adverse effects of drugs on small intestine and colon
HeatherAdministrator
03/16/10 11:23 AM
* Children's Belly Aches Don't Disappear With Antidepressant
HeatherAdministrator
03/11/10 01:14 PM
* Survey: Marijuana Use In Patients With IBS
HeatherAdministrator
01/12/10 03:17 PM
* FDA Approves Amitiza for IBS-C
HeatherAdministrator
05/23/08 10:59 AM
* Zelnorm no longer available except for emergency use
HeatherAdministrator
04/11/08 12:05 PM
* Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation.
HeatherAdministrator
02/15/08 11:20 AM
* Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome
HeatherAdministrator
01/03/08 04:45 PM
* FDA permits the restricted use of Zelnorm
HeatherAdministrator
08/09/07 11:41 AM
* Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome
HeatherAdministrator
06/20/07 01:56 PM
* Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use
HeatherAdministrator
02/04/07 04:30 PM
* Enteric Bacteria and IBS
HeatherAdministrator
11/26/06 02:51 PM
* Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
HeatherAdministrator
11/26/06 02:39 PM
* Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome
HeatherAdministrator
10/26/06 10:29 AM
* Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome
HeatherAdministrator
10/14/06 12:57 PM
* Marijuana eases chronic pain
HeatherAdministrator
07/17/06 11:49 AM
* Doctors group launches war on drug ads
HeatherAdministrator
07/17/06 11:17 AM
* New IBS drug in development in Japan
HeatherAdministrator
07/05/06 05:13 PM
* Marijuana and the gastrointestinal tract
HeatherAdministrator
06/12/06 03:38 PM
* Zelnorm Rejected Again in Europe
HeatherAdministrator
04/02/06 03:25 PM
* Antidepressants for IBS
HeatherAdministrator
03/16/06 12:31 PM
* Takeda Laxative Wins U.S. Approval for Adults
HeatherAdministrator
02/18/06 01:36 PM
* Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S.,
HeatherAdministrator
01/18/06 04:15 PM
* Hearburn Drugs Cause Diarrhea
HeatherAdministrator
01/08/06 05:10 PM
* Zelnorm fails to win EU panel backing
HeatherAdministrator
12/21/05 11:25 AM
* Non-steroidal anti-inflammatory drugs and gastrointestinal damage
HeatherAdministrator
12/08/05 12:51 PM
* Octreotide May Be Effective in Treatment of Nonconstipated IBS
HeatherAdministrator
12/08/05 12:31 PM
* Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation.
HeatherAdministrator
08/07/05 04:18 PM
* Acute Hepatitis Associated With Lotronex
HeatherAdministrator
07/24/05 02:37 PM
* FDA revisions to safety labeling for Lotronex (alosetron )
HeatherAdministrator
05/22/05 06:46 PM
* Clinical pharmacology of new motility promoting agents
HeatherAdministrator
05/22/05 06:33 PM
* Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome
HeatherAdministrator
05/08/05 06:21 PM
* Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis
HeatherAdministrator
04/24/05 03:48 PM
* Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage
HeatherAdministrator
03/28/05 01:32 PM
* Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS
HeatherAdministrator
02/19/05 05:56 PM
* Irritable Bowel Syndrome Medications Side Effects Survey
HeatherAdministrator
11/09/04 02:04 PM
* On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome
HeatherAdministrator
10/24/04 07:10 PM
* New Risk Information on Zelnorm for IBS for Women
HeatherAdministrator
07/11/04 02:18 PM
* The Relationship among Previous Antimicrobial Use and H. Pylori Infections
HeatherAdministrator
06/27/04 01:33 PM
* Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome
HeatherAdministrator
06/04/04 03:54 PM
* Pharmaceutical companies funding a number of studies into IBS in the UK
HeatherAdministrator
05/25/04 12:00 PM
* Irritable bowel syndrome helped by Paroxetine, a drug for depression
HeatherAdministrator
05/10/04 02:15 PM
* Fears cause low sales of Lotronex
HeatherAdministrator
05/10/04 01:46 PM
* Zelnorm Warning Issued by FDA
HeatherAdministrator
05/10/04 01:01 PM
* Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome
HeatherAdministrator
12/01/03 06:14 PM
* Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options
HeatherAdministrator
12/01/03 05:55 PM
* SOLVAY presses ahead with cilansetron, a new IBS drug
HeatherAdministrator
11/18/03 03:43 PM
* Measuring Treatment Effects in IBS Trials
HeatherAdministrator
10/20/03 03:30 PM
* FDA Orders Novartis To Pull Zelnorm Ads
HeatherAdministrator
10/07/03 11:25 PM
* Step-down dosage of PPI drugs for hearburn
HeatherAdministrator
09/30/03 01:26 PM
* Evaluation of drug treatment in irritable bowel syndrome
HeatherAdministrator
09/30/03 12:52 PM
* Pain Relievers and Intestinal Disorders
HeatherAdministrator
09/16/03 04:20 PM
* Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery
HeatherAdministrator
07/18/03 12:39 PM
* Antidepressants in the Treatment of IBS and Other Functional GI Disorders
HeatherAdministrator
07/18/03 12:20 PM
* Use of Antidepressants in the Treatment of IBS?
HeatherAdministrator
07/14/03 03:58 PM
* Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects
HeatherAdministrator
07/14/03 03:15 PM

Extra information
0 registered and 5 anonymous users are browsing this forum.

Moderator:  Heather 



Permissions
      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 414270

Jump to

| Privacy statement Help for IBS Home

*
UBB.threads™ 6.2


McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams

HelpForIBS.com BBB Business Review